Top

Published in:

01-01-2018 | Original Article

Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4)

Authors: Saeed Hassani, Ali Khaleghian, Shahin Ahmadian, Shaban Alizadeh, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H. Ghaffari

Published in: Annals of Hematology | Issue 1/2018

Abstract

PML-RARα perturbs the normal epigenetic setting, which is essential to oncogenic transformation in acute promyelocytic leukemia (APL). Transcription induction and recruitment of DNA methyltransferases (DNMTs) by PML-RARα and subsequent hypermethylation are components of this perturbation. Arsenic trioxide (ATO), an important drug in APL therapy, concurrent with degradation of PML-RARα induces cell cycle change and apoptosis. How ATO causes cell cycle alteration has remained largely unexplained. Here, we investigated DNA methylation patterns of cell cycle regulatory genes promoters, the effects of ATO on the methylated genes and cell cycle distribution in an APL cell line, NB4. Analysis of promoter methylation status of 22 cell cycle related genes in NB4 revealed that CCND1, CCNE1, CCNF, CDKN1A, GADD45α, and RBL1 genes were methylated 60.7, 84.6, 58.6, 8.7, 33.4, and 73.7%, respectively, that after treatment with 2 μM ATO for 48 h, turn into 0.6, 13.8, 0.1, 6.6, 10.7, and 54.5% methylated. ATO significantly reduced the expression of DNMT1, 3A, and 3B. ATO induced the expression of CCND1, CCNE1, and GADD45α genes, suppressed the expression of CCNF and CDKN1A genes, which were consistent with decreased number of cells in G1 and S phases and increased number of cells in G2/M phase. In conclusion, demethylation and alteration in the expression level of the cell cycle related genes may be possible mechanisms in ATO-induced cell cycle arrest in APL cells. It may suggest that ATO by demethylation of CCND1 and CCNE1 and their transcriptional activation accelerates G1 and S transition into the G2/M cell cycle arrest.

Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. https://doi.org/10.1182/blood-2009-03-209262 CrossRefPubMed

Martens JH, Brinkman AB, Simmer F et al (2010) PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17(2):173–185. https://doi.org/10.1016/j.ccr.2009.12.042 CrossRefPubMed

Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391(6669):811–814. https://doi.org/10.1038/35895 CrossRefPubMed

Grignani F, De Matteis S, Nervi C et al (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669):815–818. https://doi.org/10.1038/35901 CrossRefPubMed

Di Croce L, Raker VA, Corsaro M et al (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295(5557):1079–1082. https://doi.org/10.1126/science.1065173 CrossRefPubMed

Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG, Minucci S (2006) Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26(4):1288–1296. https://doi.org/10.1128/MCB.26.4.1288-1296.2006 CrossRefPubMedPubMedCentral

Villa R, Pasini D, Gutierrez A et al (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11(6):513–525. https://doi.org/10.1016/j.ccr.2007.04.009 CrossRefPubMed

Saeed S, Logie C, Stunnenberg HG, Martens JH (2011) Genome-wide functions of PML-RARalpha in acute promyelocytic leukaemia. Br J Cancer 104(4):554–558. https://doi.org/10.1038/sj.bjc.6606095 CrossRefPubMedPubMedCentral

Figueroa ME, Lugthart S, Li Y et al (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1):13–27. https://doi.org/10.1016/j.ccr.2009.11.020 CrossRefPubMedPubMedCentral

10.

Rhee I, Bachman KE, Park BH et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416(6880):552–556. https://doi.org/10.1038/416552a CrossRefPubMed

11.

Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33(1):61–65. https://doi.org/10.1038/ng1068 CrossRefPubMed

12.

Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al (2006) Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol ESMO 17(1):131–134. https://doi.org/10.1093/annonc/mdj019 CrossRef

13.

Ghavamzadeh A, Alimoghaddam K, Rostami S et al (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol : Off J Am Soc Clin Oncol 29(20):2753–2757. https://doi.org/10.1200/JCO.2010.32.2107 CrossRef

14.

Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, de The H (2005) A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7(2):143–153. https://doi.org/10.1016/j.ccr.2005.01.005 CrossRefPubMed

15.

Nasr R, Guillemin MC, Ferhi O et al (2008) Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 14(12):1333–1342. https://doi.org/10.1038/nm.1891 CrossRefPubMed

16.

Lallemand-Breitenbach V, Jeanne M, Benhenda S et al (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10(5):547–555. https://doi.org/10.1038/ncb1717 CrossRefPubMed

17.

Zhang XW, Yan XJ, Zhou ZR et al (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328(5975):240–243. https://doi.org/10.1126/science.1183424 CrossRefPubMed

18.

Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S (2006) Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 37(3):298–311CrossRefPubMed

19.

Eyvani H, Moghaddaskho F, Kabuli M et al (2016) Arsenic trioxide induces cell cycle arrest and alters DNA methylation patterns of cell cycle regulatory genes in colorectal cancer cells. Life Sci 167:67–77. https://doi.org/10.1016/j.lfs.2016.10.020 CrossRefPubMed

20.

Moghaddaskho F, Eyvani H, Ghadami M, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH (2017) Demethylation and alterations in the expression level of the cell cycle-related genes as possible mechanisms in arsenic trioxide-induced cell cycle arrest in human breast cancer cells. Tumour Biol : J Int Soc Oncodev Biol Med 39(2):1010428317692255. https://doi.org/10.1177/1010428317692255 CrossRef

21.

Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A 94(20):10907–10912CrossRefPubMedPubMedCentral

22.

Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP (2005) Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 206(3):288–298. https://doi.org/10.1016/j.taap.2004.11.017 CrossRefPubMed

23.

Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19(5):698–711. https://doi.org/10.1016/j.devcel.2010.10.005 CrossRefPubMed

24.

HY F, Shen JZ, Wu Y, Shen SF, Zhou HR, Fan LP (2010) Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep 24(2):335–343

25.

Khaleghian A, Ghaffari SH, Ahmadian S, Alimoghaddam K, Ghavamzadeh A (2014) Metabolism of arsenic trioxide in acute promyelocytic leukemia cells. J Cell Biochem 115(10):1729–1739. https://doi.org/10.1002/jcb.24838 CrossRefPubMed

26.

Hassani S, Ghaffari SH, Zaker F et al (2013) Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol 92(9):1207–1220. https://doi.org/10.1007/s00277-013-1763-8 CrossRefPubMed

27.

Cai X, Yu Y, Huang Y et al (2003) Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 17(7):1333–1337. https://doi.org/10.1038/sj.leu.2402983 CrossRefPubMed

28.

Gao F, Yi J, Yuan JQ, Shi GY, Tang XM (2004) The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 14(1):81–85. https://doi.org/10.1038/sj.cr.7290206 CrossRefPubMed

29.

Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77(5):1080–1086PubMed

30.

Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 103:55–98. https://doi.org/10.1016/B978-0-12-385493-3.00004-8 CrossRefPubMedPubMedCentral

31.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMed

32.

Belloc F, Dumain P, Boisseau MR, Jalloustre C, Reiffers J, Bernard P, Lacombe F (1994) A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 17(1):59–65. https://doi.org/10.1002/cyto.990170108 CrossRefPubMed

33.

McPherson RA, Pincus MR (2011) Clinical diagnosis and management by laboratory methods. Saunders, Philadelphia

34.

Cooper GM (2000) The cell: a molecular approach. National center for biotechnology information. https://www.ncbi.nlm.nih.gov/books/NBK9876/. Accessed 16 Nov 2017

35.

Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19(3):219–220. https://doi.org/10.1038/890 CrossRefPubMed

36.

Yang L, Rau R, Goodell MA (2015) DNMT3A in haematological malignancies. Nat Rev Cancer 15(3):152–165. https://doi.org/10.1038/nrc3895 CrossRefPubMed

37.

Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131–149CrossRefPubMed

38.

Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF (2012) GADD45 proteins: central players in tumorigenesis. Curr Mol Med 12(5):634–651CrossRefPubMedPubMedCentral

39.

Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9(6):400–414. https://doi.org/10.1038/nrc2657 CrossRefPubMedPubMedCentral

40.

Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677CrossRefPubMed

41.

Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342–348. https://doi.org/10.1038/35077213 CrossRefPubMed

42.

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042–2054. https://doi.org/10.1056/NEJMra023075 CrossRefPubMed

43.

Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074. https://doi.org/10.1056/NEJMoa1301689 CrossRef

44.

Caiafa P, Zampieri M (2005) DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem 94(2):257–265. https://doi.org/10.1002/jcb.20325 CrossRefPubMed

45.

Wolfl S, Schrader M, Wittig B (1991) Lack of correlation between DNA methylation and transcriptional inactivation: the chicken lysozyme gene. Proc Natl Acad Sci U S A 88(1):271–275CrossRefPubMedPubMedCentral

46.

Guilleret I, Benhattar J (2003) Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 289(2):326–334CrossRefPubMed

47.

Eckhardt F, Lewin J, Cortese R et al (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38(12):1378–1385. https://doi.org/10.1038/ng1909 CrossRefPubMedPubMedCentral

48.

Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705. https://doi.org/10.1016/j.cell.2007.02.005 CrossRefPubMed

49.

Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1):27–36. https://doi.org/10.1093/carcin/bgp220 CrossRefPubMed

50.

Ghaffari SH, Bashash D, Dizaji MZ, Ghavamzadeh A, Alimoghaddam K (2012) Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol : J Int Soc Oncodev Biol Med 33(1):157–172. https://doi.org/10.1007/s13277-011-0259-1 CrossRef

51.

Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15(5):2612–2624CrossRefPubMedPubMedCentral

52.

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2008) Molecular biology of the cell. Garland Science, New York

53.

Taylor BF, McNeely SC, Miller HL, Lehmann GM, MJ MC Jr, States JC (2006) p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J Pharmacol Exp Ther 318(1):142–151. https://doi.org/10.1124/jpet.106.103077 CrossRefPubMed

54.

Kong M, Barnes EA, Ollendorff V, Donoghue DJ (2000) Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction. EMBO J 19(6):1378–1388. https://doi.org/10.1093/emboj/19.6.1378 CrossRefPubMedPubMedCentral

55.

Malumbres M (2011) Physiological relevance of cell cycle kinases. Physiol Rev 91(3):973–1007. https://doi.org/10.1152/physrev.00025.2010 CrossRefPubMed

56.

Wang XW, Zhan Q, Coursen JD et al (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 96(7):3706–3711CrossRefPubMedPubMedCentral

57.

Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ Jr (1999) Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18(18):2892–2900. https://doi.org/10.1038/sj.onc.1202667 CrossRefPubMed

58.

Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR (2005) Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 24(16):2705–2714. https://doi.org/10.1038/sj.onc.1208464 CrossRefPubMed

59.

Ramachandran K, Gopisetty G, Gordian E et al (2009) Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 69(4):1527–1535. https://doi.org/10.1158/0008-5472.CAN-08-3609 CrossRefPubMed

60.

Zerbini LF, Wang Y, Czibere A et al (2004) NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci U S A 101(37):13618–13623. https://doi.org/10.1073/pnas.0402069101 CrossRefPubMedPubMedCentral

61.

Momeny M, Zakidizaji M, Ghasemi R et al (2010) Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol 27(3):833–842. https://doi.org/10.1007/s12032-009-9294-9 CrossRefPubMed

62.

Schoofs T, Muller-Tidow C (2011) DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev 37(Suppl 1):S13–S18. https://doi.org/10.1016/j.ctrv.2011.04.013 CrossRefPubMed

63.

Bernot KM, Siebenaler RF, Whitman SP et al (2013) Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia 27(12):2379–2382. https://doi.org/10.1038/leu.2013.147 CrossRefPubMed

64.

Schoofs T, Berdel WE, Muller-Tidow C (2014) Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia 28(1):1–14. https://doi.org/10.1038/leu.2013.242 CrossRefPubMed

65.

Wilting RH, Dannenberg JH (2012) Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat : Rev Commentaries Antimicrob Anticancer Chemother 15(1–2):21–38. https://doi.org/10.1016/j.drup.2012.01.008 CrossRef

66.

Shen ZX, Shi ZZ, Fang J et al (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101(15):5328–5335. https://doi.org/10.1073/pnas.0400053101 CrossRefPubMedPubMedCentral

67.

Breccia M, Lo-Coco F (2012) Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 13(7):1031–1043. https://doi.org/10.1517/14656566.2012.677436 CrossRefPubMed

68.

Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–121. https://doi.org/10.1056/NEJMoa1300874 CrossRefPubMed

Title: Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4)
Authors: Saeed Hassani
Ali Khaleghian
Shahin Ahmadian
Shaban Alizadeh
Kamran Alimoghaddam
Ardeshir Ghavamzadeh
Seyed H. Ghaffari
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 1/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3163-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma

Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population

Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page